AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Assembly Biosciences Announces $175M Equity Financings, Raises $19.60/Sh.
ByAinvest
Monday, Aug 11, 2025 5:39 pm ET1min read
Assembly Biosciences has announced the pricing of a $175 million equity financing through the sale of 5,591,840 shares of common stock and pre-funded warrants to purchase up to 1,040,820 shares of common stock, accompanied by Class A and Class B warrants to purchase up to 6,632,660 shares of common stock at a combined price of $19.60 per share.
Assembly Biosciences (NASDAQ: ASMB), a biotechnology company focused on innovative small-molecule therapeutics for serious viral diseases, has announced the pricing of a $175 million equity financing round. The offering includes 5,591,840 shares of common stock and pre-funded warrants to purchase up to 1,040,820 shares of common stock, accompanied by Class A and Class B warrants to purchase up to 6,632,660 shares of common stock at a combined price of $19.60 per share [1].The financing round, which is expected to close on August 11, 2025, involves participation from new and existing investors, including Commodore Capital, Blackstone Multi-Asset Investing, Farallon Capital Management, L.L.C., Janus Henderson Investors, RA Capital Management, and other healthcare dedicated funds [2]. Assembly Biosciences also announced a private placement with Gilead Sciences, Inc. for 2,295,920 shares of common stock and accompanying Class A and Class B warrants, under similar terms [3].
The proceeds from the offering and the private placement will be used for general corporate purposes, including advancing clinical trials and expanding research efforts. The company's latest press release highlights the significant investor confidence in Assembly Biosciences' potential, with notable participation from established investors [2].
References:
[1] https://seekingalpha.com/news/4482533-assembly-biosciences-announces-pricing-of-175-million-in-equity-financings
[2] https://www.nasdaq.com/press-release/assembly-biosciences-announces-pricing-175-million-equity-financings-2025-08-08
[3] https://www.ainvest.com/news/assembly-biosciences-raises-175m-equity-financing-2508/
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet